Edgewise Therapeutics financials
$39.19−1.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$191.4M | -$158.8M | -$114.4M | -$71.7M | -$43.2M |
| Net income | -$167.8M | -$133.8M | -$100.2M | -$67.6M | -$42.8M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 |
| EBITDA | -$189.3M | -$156.8M | -$112.8M | -$71.1M | -$42.9M |
| Operating cash flow | -$143.8M | -$109.0M | -$91.9M | -$52.6M | -$33.5M |
| Free cash flow | -$144.1M | -$110.3M | -$97.7M | -$58.2M | -$34.2M |
| Diluted shares | 102.9M | 92.4M | 63.7M | 53.6M | 37.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $61.1M | $41.7M | $86.1M | $22.0M | $15.6M |
| Short-term investments | $469.0M | $428.5M | $232.3M | $330.0M | $265.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $552.6M | $486.8M | $340.0M | $367.1M | $285.2M |
| Total liabilities | $30.3M | $27.6M | $21.2M | $20.4M | $10.8M |
| Shareholders' equity | $522.3M | $459.2M | $318.8M | $346.7M | $274.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology